|1.||Matsuoka, Nobuya: 4 articles (12/2005 - 10/2002)|
|2.||Mutoh, Seitaro: 3 articles (12/2005 - 10/2002)|
|3.||Yamazaki, Shunji: 2 articles (12/2005 - 10/2002)|
|4.||Wang, Feng: 2 articles (12/2005 - 01/2004)|
|5.||Tokita, Kenichi: 2 articles (12/2005 - 10/2002)|
|6.||Can, Ozgür Devrim: 1 article (01/2012)|
|7.||Oztürk, Yusuf: 1 article (01/2012)|
|8.||Ozkay, Yusuf: 1 article (01/2012)|
|9.||Ozkay, Umide Demir: 1 article (01/2012)|
|10.||Yamaji, Takayuki: 1 article (12/2005)|
|1.||Memory Disorders (Memory Loss)
10/01/2002 - "These results demonstrate that FK960 is more efficacious than CEIs in improving memory deficits, and that FK960 has synergistic efficacy when combined with CEIs."
06/01/1998 - "Ohkubo, I. Yamaguchi, FK960 N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate ameliorates the memory deficits in rats through a novel mechanism of action, J. "
12/01/1996 - "FK960 N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate ameliorates the memory deficits in rats through a novel mechanism of action."
10/01/2002 - "FK960 (0.1-10 mg/kg ip) significantly ameliorated the memory deficits in all three models. "
01/01/2004 - "N-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate (FK960), a novel antidementia drug, has been demonstrated to ameliorate memory deficits in various experimental models of dementia. "
|2.||Amnesia (Dissociative Amnesia)
12/27/2002 - "FK960 [N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a novel anti-dementia drug, has been shown to ameliorate experimental amnesia in rats and monkeys through activation of the somatostatinergic nervous system in the hippocampus. "
12/27/2002 - "Furthermore, FK960 has been shown to be considerably more effective in a model of spontaneous amnesia in aged rats than cholinesterase inhibitors. "
06/01/1998 - "Our previous studies have demonstrated that FK960 (FR59960; N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate), a novel antidementia piperazine derivative, exerts beneficial effects on memory deficits in various animal models of amnesia in rats [M. "
03/01/1997 - "Our previous studies demonstrated that FK960 [N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a novel antidementia piperazine derivative, exerts beneficial effects on memory deficits in various rodent models of amnesia, through activation of the somatostatin neuronal system. "
12/30/2002 - "The present study was conducted to understand the mechanism underlying the facilitatory action of FK960, an anti-dementia drug, on hippocampal neurotransmission. "
07/15/2004 - "We examined the effect of N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate (FK960), a novel anti-dementia drug, on neurotrophic factor production in cultured rat astrocytes. "
12/27/2002 - "FK960, a potential anti-dementia drug, increases synaptic density in the hippocampal CA3 region of aged rats."
06/01/1998 - "FK960, a novel potential anti-dementia drug, augments long-term potentiation in mossy fiber-CA3 pathway of guinea-pig hippocampal slices."
03/01/1997 - "From these results, we conclude that FK960 improves deficits in recognition memory associated with central cholinergic hypofunction in nonhuman primates, and we suggest that the therapeutic potential of this drug for patients with dementia should be evaluated."
|4.||Alzheimer Disease (Alzheimer's Disease)
01/01/2004 - "The potential of activation of somatostatinergic neurotransmission with FK960 in Alzheimer's disease."
01/01/2012 - "In this study, benzothiazole-piperazine compounds were synthesized by condensing the functional groups of donepezil (DNP), FK-960, and sabeluzole, which are known to have therapeutic potential against Alzheimer's disease, with the aim of obtaining new and potent anti-Alzheimer agents. "
06/01/1998 - "The magnitude of LTP of population spike recorded in CA3 pyramidal neurons was significantly augmented by perfusing FK960 (10-9-10-6 M) for 25 min before and during tetanic stimulation of the mossy fibers, whereas the basal amplitude of population spikes before tetanus was hardly affected by the drug. "
|5.||Cholinesterase Inhibitors (Anticholinesterases)
|6.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|7.||Glutamic Acid (Glutamate)
|9.||N- (1- acetylpiperidin- 4- yl)- 4- fluorobenzamide